Cardiovascular disease: risk assessment and reduction, including lipid modification

Recommendation ID

NG238/3

Question

What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

Any explanatory notes (if applicable)

For a short explanation of why the committee made this recommendation for research, see the rationale section on statins for primary prevention of CVD .

Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects.

Source guidance details

Comes from guidance: Cardiovascular disease: risk assessment and reduction, including lipid modification
Number: NG238
Date issued: December 2023

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	01/01/2024